Company

TKG Therapeutics, Inc.

TKG Therapeutics develops nucleic acid-based cancer drugs designed to activate natural immunity.

About

Founded in 2022, TKG Therapeutics develops cancer drugs that use nucleic acid aggregates and cancer-cell biomarkers to trigger innate immune responses. The company is based in Tokyo, Japan, and led by CEO Masaaki Matsui. In January 2024, it raised JPY 150 million in seed funding from Real Tech Japan and MITSUBISHI GAS CHEMICAL COMPANY, INC.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in